A blood test can accurately predict whether someone without a known risk of preeclampsia is likely to develop the potentially ...

Home > Pressemitteilung: New solutions for the RNA medicine of ... At the RNApp graduate school, young researchers are working to make RNA-based drugs safer and more effective.

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that ...

While AI offers remarkable efficiency, the pharmaceutical industry must address concerns about “black box” predictions – AI ...

About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

As it prepares to advance its lead RNA editing candidate, AIR-001, into a phase I/II trial for alpha-1 antitrypsin deficiency, Airna Corp. Inc. closed an oversubscribed $155 million series B financing ...

Building on successes in epitranscriptomics, Aqemia aims to develop novel small-molecule drugs against this emerging and ...